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Treatment of Haemophilia B with purified Factor IX (PPSB)
Dr. E. A. Lonr,rcnn, Dr. A. IInNsnN, M. J. Marrnnrl, J. J. Vnr,rrarvrr, P. F. BnuNrNc and Dr. H. C.
Hewnn
In 1947, P.q,vr,owsrv was the first to differentiate
between haemophil ia A and haemophil iaB13; type
B is found in nearly zo per cent of al1 casesa nd
is characterized by absence of a clotting factor
indicated as Factor IX upon the advice of the
International Committee on Haemostasis and
Thrombosis.
The treatment and prevention of haemorrhages
in haemophilia B is in principle the same as that in
haemophilia A. Substitution of the lacking clot-
ting factor can be, however, effected with old as
well as with fresh plasma, and even with serum,
because Factor IX differs from Factor VIII in
that it is hardly affected by ageing or clotting of
plasma.
As a result of a controlled substitution treat-
ment in three haemophilia B patient$, we report-
ed in 196r that adults suffering from severe
haemophilia B should receive, after an initial
loading dose of z-Z l, darly transfusions of t-zl
ACD plasma in order to attain and maintain a
Factor IX concentration of 25 per cent, which is
the minimum required for normal haemostasis
in the event of major surgical interventions or
after severe injurys. At the time we stated that
this can be achieved only with intensive ex-
change transfusions unless plasma fractions
are available with a considerably higher Factor
IX concentration than plasma.
In the past five years we have had occasion to
gain experience in five other haemophilia B
patients with a preparation obtained frpm human
plasma which contains a Factor IX cdncentration
5o-r5o times the normal, as calculated on a pro-
tein basis. This is the so-called PPSB!'15'16*.
General rules governing substitution of haemo-
philia B have accrued from this experience.
Mnrnons
Factor IX assay. The Factor IX assay was carried out
by the same one-stage method as that described in our
report on the treatment of haemophilia A with
cryoprecipitatelz. Only two modifications were re-
quired. Pooled normal plasma: from each of 3o indi
vidual subjects in good health (sex ratio r, mean age
about 3o), 4o ml blood was collected in a 5o-ml plastic
tube containing o.8 ml o.55 M sodium citrate, thor-
oughly mixed before being centrifuged at 2o,ooo x I'
for 3o minutes at 4"C, and stored in r-ml portions at
-25 
"C. This procedure takes 4-5 hours. Factor IX-free
plasma: from a patient with severe haemophilia B
(<I per cent Factor IX), known to possess no circul-
ating anticoagulant.
The experimental error, expressed as coefficient of
variation of the Factor IX activity, amounted to 6-9
per cent of the result obtained. For the special meas-
ures taken in assessing the Factor IX of PPSB, see
below.
Assay of Factors II, VII and X (according to Loeliger
and Kollerl ) As in assessing Factor IX, the concentra-
tion of the clotting factor in question was related to
its concentration in pooled normal plasma, in dilutions
chosen so that extrapolation in the calculation of con-
centrations is avoided.
Acquisition of PPSB. For the patients with mild
haemophilia B we acquired an amount of PPSB cor-
responding to Io I fresh pure plasma in terms of Fac-
tor IX activity; for the patient with severe haemophilia
B the amount corresponded to zo I fresh pure plasma.
Expressed in number of flasks, these amounts were 50
and roo flasks, respectively (the contents of one flask
From the Haematology Section, Department of Internal Medicine, University Hospital, Leiden, The Netherlands
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tpPSB i. the abbreviation ofProthrombin (Factor II), Proconvertin (Factor VII), Stuart factor (Factor X) and
antihaemophilic factor B (Factor IX). It was kindly placed at our disposal by Dr. Soulier and his co-workers of
the "Centre National de Transfusion Sanguine", Paris. The generous cooperation of the Paris group is gratefully
acknowledged.
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average the equivalent of about zoo ml fresh pure plas-
ma). The stock was stored at -25 oC until used. In the
flfth patient, treatment was started with the emergency
stock (ro flasks) and continued with a batch ordered
by telephone, which arrived within z4 hours. per pa-
tient we used only one batch, if possible, because the
contents of flasks of the same batch of ppSB have the
same activity.
PPSB assay. For the in-vitro assay we started with o.3
ml of the contents of a flask of PPSB dissolved in ro
ml sterile distilled water. To this we added 5.65 m1
citrated buffer (r part o.rr M sodium citrate and 4parts o.o5 M veronal buffer prepared according to
Mrcnarr,rs, pH l.d and, to neutralize the heparin
contained in PPSB (r mg per flask), o.o5 ml protamine
sulphate (diluted with buffer: r part protamine
sulphate at ro mg/ml and 14 parts buffer). Of this r/zo
diluted stock solution of PPSB (ro ml per flask) we
made dilutions of rlzo, tl4o and, r/8o in buffer, and
assessed against normal plasma in dilutions of tlro,
r l2o, r l4c and r/8o.
The Factor lX actlvity thus assessed in vitro corres-
ponded well for all batches with the data supplied by
the "Centre National de Transfusion Sanguine',
(Table II),
In order to prevent unnecessary complications as a
result of PPSB toxicity (e.g. pyrogenic effects), we test-
ed in vivo as well. This was done in one of our adults
with severe haemophilia B, patient I7916o, whom we
described in a previous publications and who volun-
teered for this test.
To avoid unnecessary risks, the contents of one
flask were dissolved not in ro ml distilled water as
prescribed, but in 9o ml physiological saline, and ad-
ministered by a 3o-minute intravenous drip. Immedia-
tely after this, and again z hours later, the Factor IX
activity in the test patient was assessed, and a tfuombe-
lastogram made. The patient's body temperature was
recorded continuously for 3 hours after the infusion.
The Factor IX activity was found to have increased
by z-5 per cent and the thrombelastographically meas-
urpd clotting time (r-time) was 2o-3o minutes (it had
exceeded 6o minutes before the infusion). In the three
batches thus assessed (nos. zzz, zz6 and 254) no side
effects were observed.
In patients I 859/65 and I rz5166, who had both
received many transfusions, the activity of PPSB was
likewise assessed in vfuo in order to rule out a circulat-
ing anticoagulant; temperature and condition were
of course kept under observation.
Mode of administration of PPSB. The administration
of PPSB after the loading dose was kept as constant
as possible. The 4 adults received PPSB by continuous
drip, and the 4-year-old boy received one daily infusion
of PPSB in 8o ml physiological saline for about 3o mi-
nutes.
In patient I z761 64 a Brawpump was used to ensure
optimally constant drip; in patient VK 4zo156 we
exclusively used a mechanical regulator; a Marlow
infusion pump (model MHRE) was used in patients
I 859i65 and. ru5166. Owing to rhe sma1l capacity of
the Braun pump patient I 276164 received infusions of
undiluted PPSB; patient YK 4zo165 was given highly
diluted PPSB (contents of one flask in 5oo ml glucose/
NaCl o.45 per cent/o.r per cent). patients I 859765 and
rz5166 received their daily dose in 3oo-5oo ml physio-
logicalsaline.
ParrBNrs
Patient I 276164 was a 25-year-old labourer,
cousin of patient HM 7516t described by us in
19618. On the basis ofthe body weight (7o kg for
a height of r7o cm) the plasma volume was calcr!-
lated as 2.8 l.
This patient is a member of a very unusual
haemophilia B family in which the severity of the
clotting disorder considerably diminishes with
increasing age6. Haemorrhages at the joints occur
only during the fust few years of life. The Factor
IX concentration is about r per cent in infants,
ro-2o per cent in young males and in an older
patient about 40 per cent.
Preoperative values between 13 per cent and
20 per cent were found in our patient. At age z, he
had a muscular haemorrhage in the left calf.
whereupon he developed talipes equinus wlnich
gave him great physical and mental discomfort.
At the patient's urging, tenotomy of the Achilles
tendon was performed on 5th March 1964. For
us this was the first operation of some importance
under PPSB protection. The operation was
performed under general anaesthesia, with surgi-
cal haemostasis without electrocoagulation. The
postoperative course was completely uneventful.
The results of the substitution therapy are pre-
sented in fig. r and Tables I, II and IIL
Patient VK 4zo165 was a 25-year-old woman in
good health, of nbrmal constitution and with a
body weight of 65 kg for a height of r72 cm.
Although personal history and family history
yielded noclue suggestive of familial haemophiliaB,
the patient was probably a carrier of haemophilia
B with a relatiyely low Factor IX concentration
(15-25 per cent). Since her childhood this patient
had shown the typical characteristics of the mild
type of haemophilia, which most physicians trea-
ting her had belittled.
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Fig. r. Clinical data obtained during substltution therapy of patient | 276164:, operation
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Time after
operation 02 1st 2nd, 3rd Attr 5th 6th 1th 8th
(days)
10th llth lzth 13th
Patient
r 276164
2700 1800 1170 1350 630
PPSB batch 160
450 720 720 400
-  p lusu tu
Patient 1200 800 800 800
VK 420165 - PPSB bqtch 222 -
600 600 300
- PPSB batch 226 -
600 600 600 400 400 400400
plasma
Patient
r ssel6s
2700 1800 1800 1800 1200 1200 1,200
PPSB batch 226 -
s20 760 720 700 550
- PIqsnn
Patient
I l2sl66
3240 1800 1260 1260 1080 1080 720 720 720 720 720 800 800 800
- Plasma --PPSB bqtch 254 -
107
160
222
226
254
260
mean of all
batches
Patients 1200 510 420 420 420 420 4004
HM 1795166 - 226 PPSB balch 260 -
I Expressed as equivalents of ml fresh normal plasma (ACD excluded).
2 0 is the day of operation.
3 Patient HM 1.795166received transfusions intermittently i.e. once daily at a 24-hour interval.
4 Half of this portion belonged to batch 254.
TasrB II: Covrp.q.RrsoN or Fecton IX acrrvrrvl rN Hospital, where a healthy daughter was born
PPSB rr.qsrs (physician in charge: Dr. J. Bennebroek Graven-
horst; then head of the department: Prof. Dr. A.
J. M. Holmer). Although the perivaginal connec-
tive tissue was found thickened as a result of
the gynaecological haemorrhage in 1963, par-
turition was free from complications and there
were only some superflcial ruptures of vaginal
epithelium. A fact contributing to the favourable
course of the parturition was the relative small-
ness of the child's head (the neonate weighea
297c. C).The umbilical cord blood had a Factor
IX activity of rro per cent. The maternal Factor
IX activity immediately post partum was 35 per
cent. In spite of this relatively high Factor IX
concentration (with a haemostasis pattern other-
wise normal for the end of pregnancy), this
woman developed a moderate atonic after-
haemorrhage and a rapidly growing \-ulvar hae-
matoma a few hours after parturition. Moreover,
the superficial vaginal ruptures bled so copiously
that the patient required blood transfusions. Since
the bleeding did not stop, PPSB treatment was
started about ro hours posl partum (fig. z and
Table I). The haemorrhage was arrested almost
immediately. The puerperal period ran a normal
Batch no. Paris2 Leiden3
220
180
200
300
180
210
215
160
200
180
300
220
120
200
1 Factor IX activity expressed in equivalent amount of
pure normal pasma.
2 Assessed in vitro using a two-stage method. The
values are 0.8 the amount indicated on the fflasks, due
to the content of ACD.
3 One-stage method.
The patient had almost fatal haemorrhages
both after a tonsillectomy and later after a vaginal
lesion of little significance*.
The patient's first pregnancy occurred in 1964.
On r6th April 196S she was admitted to the Ob-
stet-rical Department of the Leiden University
xDr. C. Merskey, Albert Einstein College of Medicine, Yeshiva University,
Factor IX deficiency on the basis of the latter haemorrhagic complication,
New York U.S.A., diagnosed
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time after
transfusion
( days )
Patient I 276164 Patient I 859165 Patient I 125166
fr
after loading dose
day 0
I
2
3
4
5
6
7
8
q
10
74
48
34
34
29
29
19
19
t9
19
t9
65
47
41
35
35
30
n a
23
22
20
1 6
27
1 1
35
35
35
)4
24
)4
J +
1 3
29
29
27
2'.7
22
23
36
J I
24
27
1 3
10
1 5
1 5
26
33
22
z+
1 A
L)
t 7
20
Mean
1 f: Factor IX activity as found in vivo.
c: Factor IX activity as calculated from theoretical considerations. For the two patients suffering from the mild
type of haemophilia B, under f the pretransfusion value is subtracted from the value found, and under c the in-
crease of Factor IX activity as expected from the PPSB infusion is given. In calculating the expected values (c)
the amount transfused during the day preceding the day under consideration is not taken into account.
+JA <2725221 i
course and the patient was discharged in good
condition 14 days post partum.
Patient I 8Sg16S was a 28-year-old technician
suffering from mild haemophilia B (Factor IX
concentration ro-I5 per cent), of otherwise nor-
mal constitution and in good health. On the basis
of the body weight (75 kg for a height of r77 cm),
the plasma volume was estimated as 3 l.
In this patient the haemophilia first manifested
itself on the occasion of a tonsillectomy at age 2
(the diagnosis was made by Dr. Ch. H. W. Lnms-
MA, Haematologist, Municipal Hospital Zuidw al,
The Hague).
On several occasions since, the patient has had
severe haemorrhages following accidental injuries
and tooth extractions. In 1958 he underwent an
operation of the patella, and the subsequent
period of mobilizatior'r was complicated by severe
haemorrhage from the surgical wound, and in-
fection, The knee-joint was consequently com-
pletely ankylosed in extension. At the same time
a very troublesome right-sided talipes equinus
developed, which at the patient's request was cor-
rected by tenotomy of the Achilles tendon. This
was done under local anaesthesia on zgth June
Folin Med. Neerl., ro ( 1967)
1965. PPSB protection at this operation ensured
normal haemostasis and entirely normal wound
healing despite the use of a thermocauter and
adrenaline administration. The patient was
discharged 14 days after the operation. For data
obtained in this case during PPSB therapy we
refer to fig. 3 and Tables I, II and III. Two months
after the substitution therapy the patient deve-
loped typical serum hepatitis, from which he
recovered completely.
Patient I rz5166 was a Ig-year-old student suf-
fering from severe haemophilia B (blood Factor
IX concentration {r per cent), but otherwise in
good health. On the basis of determination of the
blood volume with Cr51 and of the haematocrit
v alue, t}ee p I as ma v o I ume w as calculated to be z. z l.
This patient had a typical history with recurrent
haemorrhages at the joints and unmistakable if
mild arthritis of various large joints. A muscular
haemorrhage in the left forearm was followed by
Volkmann's atrophy and after a haemorrhage in
a calf (1965) he developed talipes equinus of the
left foot which handicapped him severely and for
which he underwent an operation under PPSB
protection on 6th January 1966. The postopera-
treatment of haemopltilia b with purified factor t x ( ppsb )
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Fig. z, Clinical data obtained during substitution therapy of patient YK 4zo165 duringthefust r4 days
post parrum.
tive course was uneventful. Coagulation data are
presented in fig. 4 and Tables I, II and III. This
patient, too, developed hepatitis from which he
recovered completely. Since this hepatitis oc-
curred more than 7 months after the operation
and since several blood transfusions were given
during this period, a causal relation to substitu-
tion therapy is doubtful.
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Clinical
Patient HM 1795166 was a 4-year-old boy suf-
fering frorn a moderate type of haemophilia B
(Factor IX concentration r-3 per cent ofnormal).
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He weighed 16 kg and the plasma volume was
estimated as 0.64 l. This patient is a nephew of
the previously described patient I 74o16o8.
lX  ACTIVITY (  [os .sco tc l
FACToR i l  (Hlr  y11 1e--+f , rnd X(- l  acTtvtTv
m ! .  
_
BODY -TEMPERATURE
D
oc
39
38
37
36
treatmant of haemophilia b with purified factor rx (ppsb)
EqutvAL.  FRESH PLASMA (A C O EXCL. I
:
PPSB
' : - - - - l
i -v-*-
mgta r lo l
1500 
I'1300
1000.'| 200
I''l "'
mt /hn
200 I
I
100 I
PLATELETS
FIBRINOQEN
,.6 t fll
.uu
5
*
300
200
r00
' 1  2  3  4  5  5  ?  I  I
Fig. 4. Clinical data obtained during substitution therapy
equinus.
10 11 12 13 t4 15 16 dry3
of patient I :e5166: operation for talipes
He was admitted to the surgical Department
of the University Hospital z| hours after a traf-
fic accident in which he sustained a lacerated
wound of the head and perhaps a cranial base
fracture (periorbital haematoma, suspicious X-
rays).
Partly in view of contusions of internal organs(violent abdominal pain), intensive substitution
therapy with PPSB was instituted. The patient
was discharged in good condition ro days after
admission, and the further course was uneventful
also. The results are shown in fig. 5 and Table I.
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Rssur,rs
In the four adults we attempted to maintain the
Factor IX concentration brought to a haemo-
statically effective level by means of a loading dose
with the aid of the maintenance dose. In the case
of the 4-year-old boy, who received ppSB inter-
mittently, we tried to raise the blood Factor IX
activity to a haemostatically effective level at each
infusion, and to prevent it from diminishing be-
low zo per cent. The amounts of ppSB admini-
stered and the Factor IX concentrations attained
with these amounts are presented in Table I and
figs. r through 5.
In patients I 276164 and 859/65 (flgs. r and 3)
with relatively large plasma volumes of 2.8 I and
3.o l, respectively, we attained Factor IX concen-
trations of 35 per cent to 50 per cent by means of
a loading dose of zToo ml pure plasmaequivaients
on the day of operation and a daily maintenance
dose of r3oo-r8oo ml pure fresh plasma equiva-
lents during the three subsequent days.
After reducing the PPSB dose to two-thirds the
initial value, the Factor IX concentration was
seen to diminish to values of about 3o-35 per cent.
The irregularity of the infusion in patient I 276164(fig. r) was due to poor functioning ofthe Braun
pump. In view of numerous thrombophlebitides
we were forced to discontinue ppSB administra-
tion one week after starting substitution in these
two patients. In patient | 8Sg16S (fig. :) substitu-
tion was continued by intermittent infusions of
64o ml pure plasma (i.e. 8oo ml ACD plasma)
daily, whereupon the Factor IX activity diminish-
ed to a mean value of about 25 per cent.
The puerperant patient (fig. z) required con-
siderably smaller quantities of ppSB in order to
attain Factor IX concentrations comparable to
those in the first two patients. This was in part
explained by a higher physiological production
(we measured a Factor IX activity of 35 per cent
immediately before labour), but probably also in
part by retarded degradation of the transfused
Factor IX. The slow disappearance ofFactor IX
activity after discontinuation of substitution
points in the same direction. In view of the preg-
nancy, the plasma volume cannot have been signi-
ficantly smaller than that in the other patients:
the increase jn Factor IX activity from 35 pei
cent to 55 per cent after a booster dose of rzoo
ml pure fresh plasma equivalents, indicates a
plasma volume of about 3 I (see Drscussron).
The continuous drip in the patient with severe
haemophilia B (fig. + )was particularly successful.
Non-esterifled hydrocortisone in the infusion
fluid (ro mg daily) reduced the number of throm-
bophlebitides so that substitution with ppSB
could be continued for ro days and could be
extended for zl days with a continuous drip of
8oo ml pure plasma (i.e. rooo ml ACD plasma).
The rate of disappearance of Factor IX ob-
served after discontinuation of transfusions (half-
life z4 hours) indicates that the Factor IX turn-
over was normal in this patient (see fig. 4, end of
curve).
Apart from the first injection, only minimum
activities were determined in the case of the boy(fig. S). The maximum activities attained imme-
diately after injection and the subsequent rate of
disappearance are estimates (dotted line) made on
the basis ofthe Factor IX activity ofthe ppSB as
determined in vitro and the plasma volume as ca.-
culated from the body weight of r6 kg (o.6+ l).
After a loading dose of 6oo ml pure plasma
equivalents (contents of two flasks, batch zz6),
an activity of 47 per cent might have been expected
upon virtually immediate distribution over twice
the plasma volume (i.e. virtual distribution vo-
lume; see Drscussron); we found 45 per cent.
Nine hours after the first dose a second dose of
about 6oo ml plasma equivalents was given (two
flasks of batch zz6). Given a normal Factor IX
turnover, a value approaching 5o per cent could
have been expected 24 hours after starting sub-
stitution. The value found ({3o per cent) would
seem to suggest an increased turnover at an in-
creased body temperature (38oC) due to extensive
contusions and grazing-wounds. It is not incon-
ceivable, however, that the activity of batch zz6
diminished during 14 month's storage at -z5oC;
the activity was not determined again after sto-
rage. In the further cowse of substitution with
batch z6o, Factor fX minimum values were
found to be about 20 per cent at a daily single
dose of 4zo ml plasma equivalents (about one-
third of the virtual distribution volume); these
values are in accordance with expectation given
a normal Factor IX turnover (half-life zo hours);
the patient was considerably better and afebrile
during this period (fig. S).
Side effects. Even in administration of ppSB in
physiological saline, considerably diluted and
Folia Med. Neerl., ro (1967)
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with small amounts of heparin added, the needle
had to be inserted at different sites twice daily in
the first three patients because an often very
painful and sometimes rapidly ascetding throm-
bophlebitis developed at the infusion site within
r z hours. Only in patientl tz5l66was it possible to
leave the needle in situup to 24 hours, once Io mg
non-esterified hydrocortisone was added daily;
this medication greatly reduced the severity of
phlel-ritic symptoms. .Al1 vessels returned to pa-
tency after cure of the thrombophlebitis. No
ptrlebitic symptoms were observed in the boy, who
received a single 3o-minute infusion daily of
PPSB diluted r:5 rvith pirysiological saline.
In patient I 8Sq/6S, a causal relation between
PPSB and hepatitis is possible but was not estab-
lished with certainty, for this patient received
fresh plasma transfusions also. In patient I tz5l66
the relation is very doubtful because the intervaL
between completion of substitution and the onsel
of hepatitis was over 6 months, during which
period this patient received several transfusions.
The small amounts of heparin given (up to zo
mg daily) do not disturb haemostasis because they
are too small to affect the mechanism of coagula-
tion.
DrscussroN
Patients with a Factor IX deficiency with a blood
concentration less than zo per cent of normal, can
develop vitally dangerous haemorrhages in sur-
gical interventions and after severe injuries.
This indicates that the haemostatically safe
Factor IX concentration is higher than 20 per cent.
Securing a safe blood concentration by admini-
stration of blood and plasma is possible only by
exchange transfusions, certainly in the case of
severe haemophilia B with a Factor IX concen-
tration { r per cent of normal. But in particular
in patients who have received many transfusions,
this entails appreciable risks. Plasmapheresis, like
exchange transfusion, is anything but elegant and
places considerably stress upon the patient as well
as the personnel engaged in this treatment. It is
therefore almost self-evident that administration
of purified Factor IX is preferable by far to plas-
mapheresis and exchange transfusions' This is the
more true because, in the event of complications
of wound healing, sepsis, etc., the marked in-
crease in Factor IX turnover increases the amount
of Factor IX required to attain the haemostati-
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cally safe minimum concentration to proportions
which exceed the scope of even intensive exchange
transfusionss.
Little is known with certainty about the amount
of purifled Factor IX required to ensure adequate
haemostasisl'8'16, not only because haemophilia
B is uncommon and because a clinically valid
Factor IX preparation has been available only a
few years in the form of PPSB, but also because
a reliable Factor IX assay has become available
only recently. The one-stage method as we used
it at our iaboratory until r962, yielded results with
a coefficient of variation of at least Io per cent8.
The results obtained with the two-stage method
so far used at many laboratories have a coefficient
ofvariation as high as z5 per centl.
Only in r963 did Vlr-rr.q.N4p succeed - by drastic
improvement of the one-stage metllods'5'12'1? - in
reducing the coefficient of variation of the Factor
IX activity found to 6-9 per cent. This made the
Factor IX assay sufficiently reliable for more
exact metabolic studies and a safe control of
substitution therapy. Factors of fundamental
importance in improving the accuracy of Factor
IX assay were: a) the use of the Schnitger coagu-
lometerla; b) the use of a normal standard with
constant Factor IX activity; c) the use of kaolin
as activator of the contact phase of blood coagu-
lation; d) adaptation of the dilutions of the test
plasma, on the basis of the expected Factor IX
activity, to dilutions of the standard, obviating
the need for extrapolation in calculating the Fac-
tor IX activity to be assessed.
The newly developed reliable assay reinforced
the foundation (laid in 196r) for calculating the
amount of purffied Factor IX required to ensure
the haemostatically safe Factor IX concentration.
The biological hatf-life of Factor IX was estimated
as zo ltours in a series of in part unpublished
experiments3. This value closely approaches the
rate of disappearance of purified Factor IX as
established by other authorsll.'lhe eqttilibration
hatf-tife (measure of the rate at which the equili-
brium between intravascular and extravascular
Factor IX concentrations is attained) could not
be determined with exactness. However, it seemed
unusually Jnoft (minutes) and decidedly shorter
than other investigators have reportedll. Within
ro minutes of rapid administration of the starting
dose of PPSB, only about half the dose admini-
stered was traceable intravascularly (see figs' r
treatment of haemophilia b with purffied /actor rx (ppsb)
through S). This agrees with previous personal
observationss and with the findings obtained by
the English groupl; and it suggeststhatthre virtual
distribution space of Factor lXis ttvice the intra-
vascular plasma space.
With all these data and hypotheses in mind,
and on the basis of a previously presented equa-
tion8, it is possible to calculate |he maintenance
dose (H) to be given daily by continuous drip as:
H : o.693 xz xp x L x24x rooo:  1 '7 xpxL,
t] x roo
in which H:pure plasma equivalent in ml; o.693 :
nat.log. z; z:rnultrplication factor for calculation of
the virtual distribution space of Factor lX; p :plasma
volume in litres ; L : desired level of Factor IX in per
cer.t; 24: durationolinfusion in hours; ti : biological
half-life of Factor IX.
The data compiled in Table III show that the
Factor IX activities observed during substitution
in actual practice correspond exceedingly well
with the concentrations expected, i.e. calculated
according to the above equation. These data
lend strong support to the hypothesis of rapid
distribution of the transfused Factor IX over a
virtual space twice as large as the plasma space.
Observations on the Factor IX concentrations
during the final week of substitution in our
patient with severe haemophilia B prove that this
phenomenon is not a consequence of changes
produced in Factor IX by the purification pro-
cess. In this patient, we administered from the
6th through the roth day an amount of PPSB
equivalent to 72o mI pure fresh piasma (4 flasks
of batch 254 aI r8o ml equivalents per flask), and
we continued the continuous drip for another
il, days with almost the same amount of unpuri-
fled Factor IX (8oo ml pure fresh plasma).
Throughout this period the Factor IX concentra-
tion remained virtually constant at 20 per cent
(see fig. 4 and Table III : the value of the 6th day is
still clearly influenced by the larger dose (ro8o
ml) of the preceding day).
The Factor IX concentration of a flask of
PPSB in batch 254, therefore, corresponded with
that of r8o ml pure fresh plasma, not only in
vitro butlikewise in vivo.
On the basis of the experience gained in our
patients we venture to indicate the following
generai dosage scheme (Table IV).
Taern IV: Dos.qcp ScHEME ron PPSB
Factor IX dosaget
starting dose
lst through 4th day
5th through 10th day
llth through 14th day
800 x p2
1 7 x p x 4 0 3
1 7 x p x 3 0
7 7  x p x 2 0
lThe dosage is given in ml pure plasma equivalents
per day
2 p :plasma volume in litres
340, 30 and 20 indicate the Factor IX concentrations
required during the respective periods of treatrnent,
expressed as per cent of normal.
The dosage for patients with a mild type of
haemophilia B is calculated by subtracting the
basic concentration (pre-transfusion value) from
the required concentration for each occasion"
Of course the treatment of haemophilia B is
also subject to the rule that the PPSB dosage
should be capable of being revised at any time in
view of the results of Factor IX assays carried
out twice daily. It must be borne in mind that the
turnover of the clotting factor administered can
increasee, which calls for an increase of dosage.
Comparing the equations for calculation of the
maintenance dose of Factor IX in haemophilia
B with those concerning Factor VIII in haemo-
philia A12, we flnd that they are identical, which
demonstrates that the tLffnover of Factor IX is the
seme as that of Factor VIII.
The longer biological halflife of Factor IX
(zo hours as against r4 hours for Factor VIII)
compensates an unmistakably larger virtual di-
stribution space (twice the intravascular plasma
space for Factor IX, as against 1.4 times this
space for Factor VIII). The maintenance dosages
expressed in equivalents pure fresh plasma are
accordingly the same for both types of haemo-
philia. The Factor IX dosage differs from the Fac-
tor VIII dosage only during the first 2-3 days: the
period required for loading the distribution space
in patients with haemophilia A (Factor VIII
equilibrates considerably slower than Factor IX)12.
For haemophilia A and haemophilia B alike,
Iarge amounts of concentrated clotting factor
must be available for protection in the event of
major surgical interventions; for example, for an
adult with severe haemophilia B one must have
the disposal of an amount of PPSB which in Fac-
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tor IX activity is equivalent to zo l plasma, and in
the event of a complicated postoperative course
the same amount again must be in readiness.
A few remarks may finally be made about the
most economic and least inconvenient substitu-
tion procedure. In intermittent administration of
PPSB the amount required to ensure a given
minimum concentration is undoubtedly larger
than in substitution by continuous drip, for in the
former case the average quantity of PPSB de-
graded per unit of time is larger. For the patient
intermittent administration is more convenient
and less disagreeable, particularly because PPSB
produces painful thrombophletibides at the site of
infusion. We believe that, in intermittent admini-
stration, the injections must not be spaced less
than 6 hours apart and the daily amount should
be z5 per cent larger than the daily total given by
continuous drip. In view of the possibility of
serum hepatitis, the same precautions must be
taken as in substitution therapy for haemophilia
A12.
SuvlrAnv AND coNclusroNs
Since 196o the Centre National de Transfusion
Sanguine, Paris, has produced a plasma fraction
called PPSB, which encompasses purified Factor
IX suitable for the treatment of haemophilia B.
Eight patients with haemophilia B (3 with the
severe, r with the moderate and 4 with the mild
type) were treated by us with PPSB. Our experien-
ce in these eight cases would seem to warrant the
following conclusions:
The biological activity of Factor 1X in PPSB
proves not to differ from that in fresh citrate
plasma. The turnover rate of Factor IX is of the
same order of magnitude as that of Factor VIII.
The amount of PPSB required to attain and
maintain a haemostatically effective Factor IX
concentration in the case of maior operations or
severe injuries is dependent on the plasma volume,
the severity of the haemophilia and the degree
of catabolism in the individual concerned. A
loading dose of 8o per cent of the plasma volume
raises the Factor IX activity by 4o per cent. The
required daily maintenance dose in ml, provided
it is given by continuous drip to a patient with
normal catabolism, can be calculated by the for-
mula:
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t7 x plasma volume (in litres) x required increase
in Factor IX (in per cent).
During the first four days of substitution the
Factor IX concentration must be maintained at
40 per cent; the goal during the 5th through roth
day should be 3o per cent; duringtheremaining
four days a concentration of zo per cent is prob-
ably sufficient. For an adult with severe haemo-
philia B this means a total amount of Factor IX
equivalent to some zo I pure plasma. The re-
quirement may well be doubled in the case of a
complicated postoperative course with increased
catabolism. In mild and moderate types of haemo-
philia B the dosage is lower, dependent on the
pretherapeutic Factor IX concentration. At inter-
mittent injection of PPSB at 6-hour intervals the
total dose should be about 25 per cent larger than
the total required in continuous drip.
Side effects were not observed, apart from
thrombophlebitis at the site of infusion of PPSB
given by continuous drip. This phlebitogenic effect
is unequivocally reduced by adding small quanti-
ties of non-esterified hydrocortisone to the in-
fusion fluid.
Two instances of serum hepatitis of limited se-
verity cannot be convincingly described as conse-
quences ofthe PPSB substitution therapy.
AoorNoutu
After submission of the paper, Dr. Soulier from the
Paris "National Blood Transfusion Center" kindly
informed us that none ofthe I 3 other patientswho have
been treated with PPSB batch zz6 have developed
signs or symptoms of hePatitis.
RnrBnr,Ncns
r. Brccs, R., E. Browrll, D. A. Hlt'lolrv, R' G.
MacF.rnr-aNn, J. Tl.urra, A. Elrror-Slrrrn,
G. W. R. Drxr and B. J. Ascn (r96t) The prepara-
tion and assay of a Christmas-factor (Factor IX)
concentrate and its use in the treatment of two
patients. Brit. J. IIaemat. T, 349.
z. Blernrx, Cs. and J. P. Sourrtn (1959) Pr6paration
d'une fraction riche en prothrombine, proconver-
treatment of haemophilia b with purified factor rx (ppsb) r25
tine, facteur Stuart et facteur antih6mophilique B
(fraction PPSB) Palft. Biol. 7, 2477 .
3. BmNrurous, K. M. (1964) The Hemophilias. In-
ternational Symposium Washington Chapel Hill,
The University of North Carolina Press, p. r59.
4. Irura, E. (rg6o) Haemophilia. A study of its
laboratory, clinical, genetic and social aspects bas-
ed on known haemophiliacs in Finland. Scand. J.
Clin. Lab. Invesr. suppl.45, r8.
5. KoLLER, F. and F. S:rnrurr (1965) Genetics and
the interaction of blood clotting factors. Thromb.
Diath. Haemorrft. suppl. t7, r8z.
6. Kor-rrn, F. and F. Srruurr (1965) Genetics and
the interaction of blood clotting factors. Thromb.
Diath. Haemorrh. suppl. 17,2o4.
7. I-oELrcER, E. A. and F. KorrsR. (1952) Behaviour
of Factor VII and prothrombin during late preg-
nancy and in the newborn, Acta Haemat. ,L r57.
8. Lonrrcrx., E. A. and A. HBwsnN (196r) Substitu-
tion therapy in haemophilia B. Thromb. Diath.
Ifaemorrh. 6, 39t,
9. LoELTGER, E. A.,B. v.lN orn Escn, H. C. HnlrKrn
and M. J. MntrBnN (r963) The biological disap-
pearance of prothrombin, Factors VII, IX, and X
from plasma in hypothyroidism, hyperthyroidism,
and during fever. Thromb. Diath. Haemorrh. ro,
26i.
Io. LoELTGER, E. A., A. HENSEN, M. J. MarrBrN and
H. C. Hnrrarnn (1964) Rate of synthesis of coagu-
lation factors II, VII, IX, and X during substitu-
tion theragy with PPSB. Proc. Xth Congr. Int.
Soc. BlooQ Ttransf. Stockholm, p. 1346.
rI. MfNecuf, D. and F. Josso (1963) Dur6e de vie
des facteurs VIII et IX (facteurs antih6mophiliques
A et B) inject6s a des h6mophiles. Hemostase 3,
r 39.
12. MEYER, K., J. G. EnnMssn, J. J. Vrrrrlvr, IL C.
Hrurrn and E. A. Lqr-ronn (1967) Treatment of
haemophilia A with 'concentrated Factor VIII
obtained by cryopreciiiitation from human plas-
ma. Folia Med. Neerl. io,49.
I3. PAvLowsKy , A. (tS+i Contribution to the patho-
genesis of haemophilia. Blood z, r85.
14. ScHNrrcER,H. (t956) Entwicklung eines neuartigen
Gertites zur automatischen Registrierung von Blut-
gerinnungszeiten und kritischer Beitrag zur Theorie
anfurer Messprinzipien filr gerinnungsphysiolo-
gische Untersuchungen. Thesis, Marburg.
t5. Sourrnn, J. P. (196r) Nouvelles fractions coagu-
lantes d usage th6rapeutiques. Fractions conte-
nant les facteurs plasmatiques (PPSB) ou sdriques
(CSB) adsorbables par le phosphate tricalcique.
Proc. VIIIth Congr. Europ. Soc. Haemat. Vienna,
p . 3 8 8 .
16. SouLrER, J. P., Cn. Br-ernrx and M. SrsrNsucn
(tS6q) Fractions coagulantes contenant les
facteurs de coagulation adsorbables par le phos-
phate tricalcique. Presse M6d. 72, rzz3.
17. VELTKAMe, J. J. (1961 The detection of the carriet
state in hereditary coagulation disorders. Thesis,
Leiden.
Folia Med, Neerl., ro (1967)
